Search EN / ES
Tech

Telehealth Abortion Is Still Possible Without Mifepristone

As US courts weigh the fate of mifepristone, telehealth providers are pivoting to alternative abortion protocols, leveraging asynchronous telemedicine platforms and FDA-approved oral misoprostol regimens to ensure continuity of care, even in areas where mifepristone access may be severely limited. This strategic shift underscores the adaptability of remote reproductive healthcare. Proponents argue it can mitigate the impact of potential restrictions.

Ines D (AI-assisted) 1 min read EN

US courts are weighing restrictions on mifepristone, one of two drugs used in medication abortion. Telehealth providers have already activated backup plans: prescribing misoprostol alone, a single-drug protocol that is safe, effective, and widely used globally.

What is happening

On Friday, a US federal appeals court reinstated a nationwide requirement that mifepristone must be obtained in person, effectively blocking telehealth prescriptions of the drug. The Supreme Court paused that ruling on Monday, giving a temporary reprieve until at least May 11. But providers are not waiting for the final decision.

Carafem, a telehealth abortion provider, immediately pivoted to a misoprostol-only regimen over the weekend. “We feel comfortable prescribing it,” says Melissa Grant, Carafem’s chief operations officer. Some Planned Parenthood clinics also switched to the single-drug protocol. HeyJane, another digital abortion clinic, confirmed it will do the same if necessary.

The two-drug vs. single-drug protocol

A standard medication abortion uses two pills: mifepristone blocks progesterone to stop the pregnancy from progressing; misoprostol causes uterine contractions to expel the tissue. The dual regimen is slightly more effective and has fewer side effects than misoprostol alone.

Misoprostol was originally developed to treat gastric ulcers and has been used for medication abortion since the late 1980s. It remains the primary method in many countries where mifepristone is unavailable. The World Health Organization, the American College of Obstetricians and Gynecologists, the Society of Family Planning, and the National Abortion Federation all endorse the misoprostol-only protocol when mifepristone is not accessible.

Most people using the dual regimen need only one dose of misoprostol. With the single-drug protocol, three or more doses are required, which can cause more intense or prolonged side effects such as nausea, vomiting, and uterine cramping. Providers recommend having anti-nausea and pain medication on hand.

Telehealth and access

Mifepristone was approved by the FDA in 2000. In April 2021, during the Covid-19 pandemic, the FDA allowed it to be obtained by mail instead of in person. The agency permanently lifted the in-person dispensing requirement in 2023. After the Supreme Court overturned Roe v. Wade in 2022, medication abortion via telehealth became a sought-after option, especially for patients in states with abortion restrictions. Approximately one in three abortions in the first half of 2025 used abortion pills obtained through telehealth, according to public health nonprofit Plan C.

Carafem has offered misoprostol-only medication abortions since

Sources 1

  1. 01 Source https://www.wired.com/story/telehealth-abortion-is-still-possible-without-mifepristone/
Similar Articles

More articles like this

Tech 1 min

Bumble’s paying users are slipping as it bets on an overhaul later this year

Bumble's paying user base is experiencing a significant decline, with a 21% drop in the latest quarter, as the dating app's leadership intentionally redirects resources towards a major overhaul scheduled for later this year. This strategic pivot comes as the company seeks to revamp its core offerings and reinvigorate user engagement. The exact nature of the planned changes remains unclear.
Tech 1 min

Altara secures $7M to bridge the data gap that’s slowing down physical sciences

A breakthrough in data integration is poised to accelerate the pace of physical sciences research, as Altara's $7 million funding injection fuels the development of an AI-driven platform that seamlessly unifies disparate data sources, including spreadsheets and legacy systems, to diagnose failures and optimize research and development workflows. By bridging the data gap, Altara's technology has the potential to unlock new discoveries and streamline the R&D process. This strategic investment is expected to drive innovation in fields such as materials science and engineering.
Tech 1 min

Intel is bringing a chip to every computing category at Computex. The last time it could do that, it was the company everyone was trying to catch.

Intel’s Computex 2026 lineup marks its first full-stack silicon unification since the Core 2 Duo era, extending 3 nm Panther Lake client dies into handhelds via Arc G3 and G3 Extreme GPUs—an integrated architecture play that could finally challenge Arm’s dominance in mobile form factors. With a single process node spanning laptops, desktops, and now ultra-compact devices, Intel is betting on economies of scale to reclaim its once-unassailable lead.
Tech 1 min

Lucid Motors doesn’t know how many EVs it will build this year

Lucid Motors' abrupt abandonment of production targets underscores the precarious balance between inventory management and cost-cutting in the electric vehicle sector, where bloated stockpiles can quickly become a financial liability. The company's decision to forgo quarterly projections suggests a struggle to reconcile supply chain realities with investor expectations. As Lucid's inventory levels continue to swell, the EV maker's financial trajectory hangs in the balance.
Tech 1 min

Google Home’s Gemini AI can handle more complicated requests

Google Home’s Gemini 3.1 upgrade quietly transforms the smart speaker into a true multi-step agent, parsing compound commands like “reschedule tomorrow’s 9 a.m. meeting, then text Mom the new time” without explicit sequencing. The update also patches device misidentification bugs and adds drag-and-drop event reordering—shifting from rigid voice-tree logic to a fluid, stateful task engine.
Tech 1 min

China’s humanoid robot boom faces reality check as 150 companies chase a market where only 23% of buyers are satisfied

China's humanoid robot industry is facing a reckoning as a surge in production from over 150 companies fails to meet demand, with a staggering 77% of buyers expressing dissatisfaction with their purchases, despite the sector's dominance in global shipments, which reached 90% in 2025. The market's two largest players, Unitree and AgiBot, are poised to go public, valuing them at a combined $13 billion. Morgan Stanley has doubled its delivery forecast for the Chinese market this year.